SlideShare une entreprise Scribd logo
1  sur  30
Presented by :
Pankaj soni
M.Pharm(1st sem)
Ph’Analysis
INTRODUCTION
Webster's dictionary defines impurity as something that is
impure or makes something else impure. An impure substance
may be defined as follows: a substance of interest mixed or
impregnated with an extraneous or usually inferior substance.
2
TERMINOLOOGY
COMMONLY USED TERMINOLOGY :
• Starting material(s)
• Intermediates
• Penultimate intermediate (Final intermediate)
• By-products
• Transformation products(similar to by-products)
• Interaction products
• Related products(similar to the drug substance)
• Degradation products
3
COMPENDIAL TERMINOLOGY :
▪ Foreign substances
▪ Toxic impurities
▪ Concomitant components
▪ Signal impurities
▪ Ordinary impurities
▪ Organic volatile impurities (OVIs)
4
A. Organic impurities
a. starting materials
b. Process-related impurities
c. Intermediates
d. Degradation products.
B. Inorganic impurities
a. Salts
b. Catalysts
c. Ligands
d. Heavy metals or other residual metals.
C. Other materials
a. Filter aids
b. Charcoal. 5
D. Residual solvents:
Organic and inorganic liquids used during
production and/or crystallization.
6
Identification and qualification
thresholds of impurities
The International Conference on Harmonisation addresses
questions relating to impurities as follows [6]:
Q1A (R) stability testing of new drug substances and
products
Q3A (R) impurities in drug substances
Q3B (R) impurities in drug products
Q3C impurities: residual solvents
Q6A specifications: test procedures and acceptance criteria
for new drug substances and new drug products; chemical
substances
7
ICH guidelines for the identification and qualification
threshold of impurities and degradation products are
provided
in Table 1.
8
As can be seen from the data in Table 2, ICH
treats the
degradation products slightly differently than
impurities even
though for all intents and purposes the
degradation products are
impurities.
9
SOURCES OF IMPURITIES
Synthesis-related impurities :
Impurities in a drug substance or a new
chemical entity
(NCE) originate mainly during the synthetic
process from raw
materials, solvents, intermediates, and by-
products.
10
Formulation-related impurities:
A number of impurities in a drug product can
arise out of interactions with excipients used to
formulate a drug product.
Furthermore, in the process of formulation, a
drug substance is subjected to a variety of
conditions that can lead to its
degradation or other deleterious reactions. For
example,
if heat is used for drying or for other reasons, it
can facilitate degradation of thermally labile
drug substances.
Solutions and suspensions are potentially prone
to degradation
that is due to hydrolysis or solvolysis etc.
11
Degradation-related impurities
A number of impurities can be produced because of API
Degradation or other interactions on storage.
Therefore, it is very important to conduct stability studies
to predict, evaluate, and ensure drug product safety [7].
Stability studies include evaluation of stability of API,
preformulation studies to evaluate compatibility of API
with the excipients to determine its stability in the
formulation matrix, accelerated stability evaluations of
the test or final drug product, stability evaluation via
kinetic studies and
projection of expiration date, routine stability studies of
drug products in marketed, sample or dispensed package
under various conditions of temperature light, and
humidity
12
The stability studies under various exaggerated conditions of
temperature, humidity, and light can help us determine what
potential impurities can be produced by degradation reactions.
13
Selective analytical
methodologies
Development of a new drug mandates that meaningful and
reliable analytical data be generated at various steps of the
new drug development . Ensuring the safety of a new
pharmaceutical compound or drug requires that it meet the
established purity standards as a chemical entity or when
admixed with animal feeds for toxicity studies or
pharmaceutical excipients for human use.
Furthermore, it should exhibit excellent stability
throughout its shelf life. These requirements demand that the
analytical methodology that is used be sensitive enough to
measure low levels of impurities.
14
A variety of methods are available for
monitoring impurities.
The primary criterion is the ability to
differentiate between the compounds of
interest.
This requirement reduces the availability
of methods primarily to spectroscopic and
separation methods or a combination
thereof.
15
Spectroscopic methods
The following spectroscopic methods can be
used:
▪ Ultraviolet (UV)
▪ Infrared (IR)
▪ Nuclear magnetic resonance (NMR)
▪ Mass spectrometry (MS)
16
SEPARATION METHODS
The following separation methods can be
used:
▪ Thin-layer chromatography (TLC)
▪ Gas chromatography (GC)
▪ High-pressure liquid chromatography (HPLC)
▪ Capillary electrophoresis (CE)
▪ Supercritical fluid chromatography (SFC)
17
TLC: A broad range of compounds can be resolved using
TLC by utilizing a variety of different plates and mobile
phases. The primary difficulties related to this method are
limited resolution, detection, and ease of quantification. The
greatest advantages are the ease of use and low cost.
GC: Gas chromatography is a very useful technique for
quantification.
It can provide the desired resolution, selectivity, and
ease of quantification. However, the primary limitation is
that the sample must be volatile or has to be made volatile
by derivatization. This technique is very useful for organic
volatile impurities.
HPLC: This is a useful technique with applications that have
been significantly extended for the pharmaceutical chemist
by the use of a variety of detectors such as fluorescence,
electrometric, MS, etc
18
Capillary electrophoresis : a useful technique
when very low quantities of samples are available
and high resolution is required. The primary
difficulty is assuring reproducibility of
the injected samples.
Supercritical fluid chromatography: offers some of
the advantages of GC in terms of detection and
HPLC in terms of separations, in that volatility of
the sample is not of paramount importance. This
technique is still evolving, and its greatest
application has been found in the extraction of
samples.
19
Hyphenated methods
▪ GC–MS
▪ LC–MS
▪ LC–DAD–MS
▪ LC–NMR
▪ LC–DAD–NMR–MS
▪ LC–MS–MS
20
Impurity profiling
The name impurity profiling is commonly reflected to be a set of
analytical
activities targeting at the detection, identification or structure
characterisation and
quantitative estimation of organic, inorganic impurities, and
residual solvents, in drug
substances as well as in a drug products.
Reporting, identification and qualification of
impurities are required for determining the biological safety of
each impurity.
21
Samples to be profiled :
Impurity profiling should be done for the
following samples:
▪ Active ingredient
▪ Process check (synthesis or formulation)
▪ Final product.
22
Components seen in a profile :
Ideally, an impurity profile should show the
following:
▪ Synthesis-related impurities
▪ Formulation-related impurities
▪ Degradation products
▪ Interaction products
23
Isolating impurities
The following methods have been used for isolation of
impurities:
▪ Solid-phase extraction
▪ Liquid–liquid extraction
▪ Accelerated solvent extraction
▪ Supercritical fluid extraction
▪ Column chromatography
▪ Flash chromatography
▪ Thin-layer chromatography
▪ Gas chromatography
▪ High-pressure liquid chromatography
▪ Capillary electrophoresis
▪ Supercritical fluid chromatography.
24
Isolation should be initiated based on simple
extraction or partition methods. It may be possible to
extract impurities selectively on the basis of acidity,
basicity, or neutrality.
The extraction process usually involves liquid–liquid
extraction, where one phase is an aqueous solution
and the other is an organic phase that is nonpolar.
By appropriate adjustment of the pH of the aqueous
solution, one can extract acidic, basic, or neutral
impurities. Further separations can be made by
chromatographic methods. Frequently, the isolation
methods tend to be the same methods that are used
for analysis.
25
Characterization of impurities
The characterization of impurities is generally achieved by
the following means:
▪ Matching retention data
▪ UV
▪ IR
▪ NMR
▪ MS
Once an impurity has been detected, it becomes necessary to
estimate its content. Detectability frequently means that a
given component provides a signal at least twice that of
background noise or the baseline.
26
27
Application of Impurity Profiling
Numerous applications have been sought in the areas
of drug designing and in monitoring quality, stability,
and safety of pharmaceutical compounds, whether
produced synthetically, extracted from natural
products or produced by recombinant methods.
The applications include alkaloids, amines, amino
acids, analgesics, antibacterials, anticonvulsants,
antidepressant, tranquilizers, antineoplastic agents,
local anesthetics, macromolecules, steroids etc.
Some commonly found impurities in drug and their
identification method are:
28
29
30

Contenu connexe

Tendances

Impurities in Drug Substance & in Drug Product
Impurities in Drug Substance & in Drug ProductImpurities in Drug Substance & in Drug Product
Impurities in Drug Substance & in Drug Product
Kamal Ambalia
 

Tendances (20)

Residual solvents
Residual solventsResidual solvents
Residual solvents
 
Impurities in residual solvents
Impurities in residual solventsImpurities in residual solvents
Impurities in residual solvents
 
ICH Q2 Analytical Method Validation
ICH Q2  Analytical Method ValidationICH Q2  Analytical Method Validation
ICH Q2 Analytical Method Validation
 
Impurity Profile
Impurity ProfileImpurity Profile
Impurity Profile
 
Stability Testing of Phytopharmaceuticals
Stability Testing of PhytopharmaceuticalsStability Testing of Phytopharmaceuticals
Stability Testing of Phytopharmaceuticals
 
Basics impurity profiling and degradent characterization[134]
Basics impurity profiling and degradent characterization[134]Basics impurity profiling and degradent characterization[134]
Basics impurity profiling and degradent characterization[134]
 
Analytical methods validation as per ich & usp
Analytical methods validation as per ich & uspAnalytical methods validation as per ich & usp
Analytical methods validation as per ich & usp
 
IMPURITY PROFILING (SOURCES OF IMPURITIES)
IMPURITY PROFILING (SOURCES OF IMPURITIES)IMPURITY PROFILING (SOURCES OF IMPURITIES)
IMPURITY PROFILING (SOURCES OF IMPURITIES)
 
Impurities in drug substance (ich q3 a)
Impurities in drug substance (ich q3 a)Impurities in drug substance (ich q3 a)
Impurities in drug substance (ich q3 a)
 
Analytical method validation as per ich and usp
Analytical method validation as per ich and usp Analytical method validation as per ich and usp
Analytical method validation as per ich and usp
 
Qualification of analytical instruments
Qualification of analytical instrumentsQualification of analytical instruments
Qualification of analytical instruments
 
Calibaration and validation of hplc
Calibaration and validation of hplcCalibaration and validation of hplc
Calibaration and validation of hplc
 
extraction of drug from biological matrix.pptx
extraction of drug from biological matrix.pptxextraction of drug from biological matrix.pptx
extraction of drug from biological matrix.pptx
 
Elemental Impurities by Shiv Kalia.pptx
Elemental Impurities by Shiv Kalia.pptxElemental Impurities by Shiv Kalia.pptx
Elemental Impurities by Shiv Kalia.pptx
 
Impurities in Drug Substance & in Drug Product
Impurities in Drug Substance & in Drug ProductImpurities in Drug Substance & in Drug Product
Impurities in Drug Substance & in Drug Product
 
IMPURITIES AND STABILITY STUDIES
IMPURITIES AND STABILITY STUDIESIMPURITIES AND STABILITY STUDIES
IMPURITIES AND STABILITY STUDIES
 
IMPURITIES OF NEW DRUG PRODUCTS
IMPURITIES OF NEW DRUG PRODUCTS IMPURITIES OF NEW DRUG PRODUCTS
IMPURITIES OF NEW DRUG PRODUCTS
 
Ion pair chromatography final
Ion pair chromatography finalIon pair chromatography final
Ion pair chromatography final
 
ICH- Q3 Impurity
ICH- Q3 ImpurityICH- Q3 Impurity
ICH- Q3 Impurity
 
Qualification of instrumets
Qualification of instrumetsQualification of instrumets
Qualification of instrumets
 

Similaire à Basics of Impurity Profiling

Development and estimation of carvedilol in oral dosage form using HPLC method
Development and estimation of carvedilol in oral dosage form using HPLC methodDevelopment and estimation of carvedilol in oral dosage form using HPLC method
Development and estimation of carvedilol in oral dosage form using HPLC method
BRNSSPublicationHubI
 
Analysis of parenteral dosage forms bjl final seminar
Analysis of parenteral dosage forms bjl final seminarAnalysis of parenteral dosage forms bjl final seminar
Analysis of parenteral dosage forms bjl final seminar
Patel Parth
 
Indu...impurity profiling of api’s using rp hplc as per
Indu...impurity profiling of api’s using rp hplc as perIndu...impurity profiling of api’s using rp hplc as per
Indu...impurity profiling of api’s using rp hplc as per
hdghcfgfgftf
 
Staff Meeting Powerpoint
Staff Meeting PowerpointStaff Meeting Powerpoint
Staff Meeting Powerpoint
Johnny Mackey
 

Similaire à Basics of Impurity Profiling (20)

Impurity and food agents.seminar.pptx
Impurity and food agents.seminar.pptxImpurity and food agents.seminar.pptx
Impurity and food agents.seminar.pptx
 
Chanduppt2
Chanduppt2Chanduppt2
Chanduppt2
 
AN-4 SINDHU.pptx
AN-4 SINDHU.pptxAN-4 SINDHU.pptx
AN-4 SINDHU.pptx
 
Bioanalysis overview
Bioanalysis overviewBioanalysis overview
Bioanalysis overview
 
Development and estimation of carvedilol in oral dosage form using HPLC method
Development and estimation of carvedilol in oral dosage form using HPLC methodDevelopment and estimation of carvedilol in oral dosage form using HPLC method
Development and estimation of carvedilol in oral dosage form using HPLC method
 
Compendial testing
Compendial testingCompendial testing
Compendial testing
 
Difference between HPLC and HPTLC and Applications.
Difference between HPLC and HPTLC and Applications.Difference between HPLC and HPTLC and Applications.
Difference between HPLC and HPTLC and Applications.
 
Pesticide residue
Pesticide residuePesticide residue
Pesticide residue
 
Analysis of parenteral dosage forms bjl final seminar
Analysis of parenteral dosage forms bjl final seminarAnalysis of parenteral dosage forms bjl final seminar
Analysis of parenteral dosage forms bjl final seminar
 
quality control of herbal drugs
quality control of herbal drugsquality control of herbal drugs
quality control of herbal drugs
 
Impurities in API , types and their sources including genotoxic impurities
Impurities in API , types and their sources including genotoxic impuritiesImpurities in API , types and their sources including genotoxic impurities
Impurities in API , types and their sources including genotoxic impurities
 
Test for active pharmaceutical raw materials in herbal drugs, Pharmacognostic...
Test for active pharmaceutical raw materials in herbal drugs, Pharmacognostic...Test for active pharmaceutical raw materials in herbal drugs, Pharmacognostic...
Test for active pharmaceutical raw materials in herbal drugs, Pharmacognostic...
 
HPLC In Pharmaceutical sciences
 HPLC In Pharmaceutical sciences HPLC In Pharmaceutical sciences
HPLC In Pharmaceutical sciences
 
Sagar kanade m pharm indrustial project
Sagar kanade m pharm indrustial projectSagar kanade m pharm indrustial project
Sagar kanade m pharm indrustial project
 
METHOD VALIDATION AND STABILITY METHOD OF TELMISARTAN AND EFONIDIPINE IN RPHP...
METHOD VALIDATION AND STABILITY METHOD OF TELMISARTAN AND EFONIDIPINE IN RPHP...METHOD VALIDATION AND STABILITY METHOD OF TELMISARTAN AND EFONIDIPINE IN RPHP...
METHOD VALIDATION AND STABILITY METHOD OF TELMISARTAN AND EFONIDIPINE IN RPHP...
 
High performance Liquid Chromatography
High performance Liquid ChromatographyHigh performance Liquid Chromatography
High performance Liquid Chromatography
 
Indu...impurity profiling of api’s using rp hplc as per
Indu...impurity profiling of api’s using rp hplc as perIndu...impurity profiling of api’s using rp hplc as per
Indu...impurity profiling of api’s using rp hplc as per
 
High performance liquid_chromatography
High performance liquid_chromatographyHigh performance liquid_chromatography
High performance liquid_chromatography
 
Staff Meeting Powerpoint
Staff Meeting PowerpointStaff Meeting Powerpoint
Staff Meeting Powerpoint
 
A brief review on development and validation of hplc method.
A brief review on development and validation of hplc method.A brief review on development and validation of hplc method.
A brief review on development and validation of hplc method.
 

Dernier

Asymmetry in the atmosphere of the ultra-hot Jupiter WASP-76 b
Asymmetry in the atmosphere of the ultra-hot Jupiter WASP-76 bAsymmetry in the atmosphere of the ultra-hot Jupiter WASP-76 b
Asymmetry in the atmosphere of the ultra-hot Jupiter WASP-76 b
Sérgio Sacani
 
Cyathodium bryophyte: morphology, anatomy, reproduction etc.
Cyathodium bryophyte: morphology, anatomy, reproduction etc.Cyathodium bryophyte: morphology, anatomy, reproduction etc.
Cyathodium bryophyte: morphology, anatomy, reproduction etc.
Silpa
 
THE ROLE OF BIOTECHNOLOGY IN THE ECONOMIC UPLIFT.pptx
THE ROLE OF BIOTECHNOLOGY IN THE ECONOMIC UPLIFT.pptxTHE ROLE OF BIOTECHNOLOGY IN THE ECONOMIC UPLIFT.pptx
THE ROLE OF BIOTECHNOLOGY IN THE ECONOMIC UPLIFT.pptx
ANSARKHAN96
 
CYTOGENETIC MAP................ ppt.pptx
CYTOGENETIC MAP................ ppt.pptxCYTOGENETIC MAP................ ppt.pptx
CYTOGENETIC MAP................ ppt.pptx
Silpa
 
Phenolics: types, biosynthesis and functions.
Phenolics: types, biosynthesis and functions.Phenolics: types, biosynthesis and functions.
Phenolics: types, biosynthesis and functions.
Silpa
 
Human genetics..........................pptx
Human genetics..........................pptxHuman genetics..........................pptx
Human genetics..........................pptx
Silpa
 
POGONATUM : morphology, anatomy, reproduction etc.
POGONATUM : morphology, anatomy, reproduction etc.POGONATUM : morphology, anatomy, reproduction etc.
POGONATUM : morphology, anatomy, reproduction etc.
Silpa
 

Dernier (20)

Asymmetry in the atmosphere of the ultra-hot Jupiter WASP-76 b
Asymmetry in the atmosphere of the ultra-hot Jupiter WASP-76 bAsymmetry in the atmosphere of the ultra-hot Jupiter WASP-76 b
Asymmetry in the atmosphere of the ultra-hot Jupiter WASP-76 b
 
Climate Change Impacts on Terrestrial and Aquatic Ecosystems.pptx
Climate Change Impacts on Terrestrial and Aquatic Ecosystems.pptxClimate Change Impacts on Terrestrial and Aquatic Ecosystems.pptx
Climate Change Impacts on Terrestrial and Aquatic Ecosystems.pptx
 
Thyroid Physiology_Dr.E. Muralinath_ Associate Professor
Thyroid Physiology_Dr.E. Muralinath_ Associate ProfessorThyroid Physiology_Dr.E. Muralinath_ Associate Professor
Thyroid Physiology_Dr.E. Muralinath_ Associate Professor
 
Cyathodium bryophyte: morphology, anatomy, reproduction etc.
Cyathodium bryophyte: morphology, anatomy, reproduction etc.Cyathodium bryophyte: morphology, anatomy, reproduction etc.
Cyathodium bryophyte: morphology, anatomy, reproduction etc.
 
THE ROLE OF BIOTECHNOLOGY IN THE ECONOMIC UPLIFT.pptx
THE ROLE OF BIOTECHNOLOGY IN THE ECONOMIC UPLIFT.pptxTHE ROLE OF BIOTECHNOLOGY IN THE ECONOMIC UPLIFT.pptx
THE ROLE OF BIOTECHNOLOGY IN THE ECONOMIC UPLIFT.pptx
 
Human & Veterinary Respiratory Physilogy_DR.E.Muralinath_Associate Professor....
Human & Veterinary Respiratory Physilogy_DR.E.Muralinath_Associate Professor....Human & Veterinary Respiratory Physilogy_DR.E.Muralinath_Associate Professor....
Human & Veterinary Respiratory Physilogy_DR.E.Muralinath_Associate Professor....
 
CYTOGENETIC MAP................ ppt.pptx
CYTOGENETIC MAP................ ppt.pptxCYTOGENETIC MAP................ ppt.pptx
CYTOGENETIC MAP................ ppt.pptx
 
FAIRSpectra - Enabling the FAIRification of Spectroscopy and Spectrometry
FAIRSpectra - Enabling the FAIRification of Spectroscopy and SpectrometryFAIRSpectra - Enabling the FAIRification of Spectroscopy and Spectrometry
FAIRSpectra - Enabling the FAIRification of Spectroscopy and Spectrometry
 
Dr. E. Muralinath_ Blood indices_clinical aspects
Dr. E. Muralinath_ Blood indices_clinical  aspectsDr. E. Muralinath_ Blood indices_clinical  aspects
Dr. E. Muralinath_ Blood indices_clinical aspects
 
Bhiwandi Bhiwandi ❤CALL GIRL 7870993772 ❤CALL GIRLS ESCORT SERVICE In Bhiwan...
Bhiwandi Bhiwandi ❤CALL GIRL 7870993772 ❤CALL GIRLS  ESCORT SERVICE In Bhiwan...Bhiwandi Bhiwandi ❤CALL GIRL 7870993772 ❤CALL GIRLS  ESCORT SERVICE In Bhiwan...
Bhiwandi Bhiwandi ❤CALL GIRL 7870993772 ❤CALL GIRLS ESCORT SERVICE In Bhiwan...
 
300003-World Science Day For Peace And Development.pptx
300003-World Science Day For Peace And Development.pptx300003-World Science Day For Peace And Development.pptx
300003-World Science Day For Peace And Development.pptx
 
Factory Acceptance Test( FAT).pptx .
Factory Acceptance Test( FAT).pptx       .Factory Acceptance Test( FAT).pptx       .
Factory Acceptance Test( FAT).pptx .
 
Phenolics: types, biosynthesis and functions.
Phenolics: types, biosynthesis and functions.Phenolics: types, biosynthesis and functions.
Phenolics: types, biosynthesis and functions.
 
FAIRSpectra - Enabling the FAIRification of Analytical Science
FAIRSpectra - Enabling the FAIRification of Analytical ScienceFAIRSpectra - Enabling the FAIRification of Analytical Science
FAIRSpectra - Enabling the FAIRification of Analytical Science
 
Molecular markers- RFLP, RAPD, AFLP, SNP etc.
Molecular markers- RFLP, RAPD, AFLP, SNP etc.Molecular markers- RFLP, RAPD, AFLP, SNP etc.
Molecular markers- RFLP, RAPD, AFLP, SNP etc.
 
Human genetics..........................pptx
Human genetics..........................pptxHuman genetics..........................pptx
Human genetics..........................pptx
 
Role of AI in seed science Predictive modelling and Beyond.pptx
Role of AI in seed science  Predictive modelling and  Beyond.pptxRole of AI in seed science  Predictive modelling and  Beyond.pptx
Role of AI in seed science Predictive modelling and Beyond.pptx
 
POGONATUM : morphology, anatomy, reproduction etc.
POGONATUM : morphology, anatomy, reproduction etc.POGONATUM : morphology, anatomy, reproduction etc.
POGONATUM : morphology, anatomy, reproduction etc.
 
PSYCHOSOCIAL NEEDS. in nursing II sem pptx
PSYCHOSOCIAL NEEDS. in nursing II sem pptxPSYCHOSOCIAL NEEDS. in nursing II sem pptx
PSYCHOSOCIAL NEEDS. in nursing II sem pptx
 
CURRENT SCENARIO OF POULTRY PRODUCTION IN INDIA
CURRENT SCENARIO OF POULTRY PRODUCTION IN INDIACURRENT SCENARIO OF POULTRY PRODUCTION IN INDIA
CURRENT SCENARIO OF POULTRY PRODUCTION IN INDIA
 

Basics of Impurity Profiling

  • 1. Presented by : Pankaj soni M.Pharm(1st sem) Ph’Analysis
  • 2. INTRODUCTION Webster's dictionary defines impurity as something that is impure or makes something else impure. An impure substance may be defined as follows: a substance of interest mixed or impregnated with an extraneous or usually inferior substance. 2
  • 3. TERMINOLOOGY COMMONLY USED TERMINOLOGY : • Starting material(s) • Intermediates • Penultimate intermediate (Final intermediate) • By-products • Transformation products(similar to by-products) • Interaction products • Related products(similar to the drug substance) • Degradation products 3
  • 4. COMPENDIAL TERMINOLOGY : ▪ Foreign substances ▪ Toxic impurities ▪ Concomitant components ▪ Signal impurities ▪ Ordinary impurities ▪ Organic volatile impurities (OVIs) 4
  • 5. A. Organic impurities a. starting materials b. Process-related impurities c. Intermediates d. Degradation products. B. Inorganic impurities a. Salts b. Catalysts c. Ligands d. Heavy metals or other residual metals. C. Other materials a. Filter aids b. Charcoal. 5
  • 6. D. Residual solvents: Organic and inorganic liquids used during production and/or crystallization. 6
  • 7. Identification and qualification thresholds of impurities The International Conference on Harmonisation addresses questions relating to impurities as follows [6]: Q1A (R) stability testing of new drug substances and products Q3A (R) impurities in drug substances Q3B (R) impurities in drug products Q3C impurities: residual solvents Q6A specifications: test procedures and acceptance criteria for new drug substances and new drug products; chemical substances 7
  • 8. ICH guidelines for the identification and qualification threshold of impurities and degradation products are provided in Table 1. 8
  • 9. As can be seen from the data in Table 2, ICH treats the degradation products slightly differently than impurities even though for all intents and purposes the degradation products are impurities. 9
  • 10. SOURCES OF IMPURITIES Synthesis-related impurities : Impurities in a drug substance or a new chemical entity (NCE) originate mainly during the synthetic process from raw materials, solvents, intermediates, and by- products. 10
  • 11. Formulation-related impurities: A number of impurities in a drug product can arise out of interactions with excipients used to formulate a drug product. Furthermore, in the process of formulation, a drug substance is subjected to a variety of conditions that can lead to its degradation or other deleterious reactions. For example, if heat is used for drying or for other reasons, it can facilitate degradation of thermally labile drug substances. Solutions and suspensions are potentially prone to degradation that is due to hydrolysis or solvolysis etc. 11
  • 12. Degradation-related impurities A number of impurities can be produced because of API Degradation or other interactions on storage. Therefore, it is very important to conduct stability studies to predict, evaluate, and ensure drug product safety [7]. Stability studies include evaluation of stability of API, preformulation studies to evaluate compatibility of API with the excipients to determine its stability in the formulation matrix, accelerated stability evaluations of the test or final drug product, stability evaluation via kinetic studies and projection of expiration date, routine stability studies of drug products in marketed, sample or dispensed package under various conditions of temperature light, and humidity 12
  • 13. The stability studies under various exaggerated conditions of temperature, humidity, and light can help us determine what potential impurities can be produced by degradation reactions. 13
  • 14. Selective analytical methodologies Development of a new drug mandates that meaningful and reliable analytical data be generated at various steps of the new drug development . Ensuring the safety of a new pharmaceutical compound or drug requires that it meet the established purity standards as a chemical entity or when admixed with animal feeds for toxicity studies or pharmaceutical excipients for human use. Furthermore, it should exhibit excellent stability throughout its shelf life. These requirements demand that the analytical methodology that is used be sensitive enough to measure low levels of impurities. 14
  • 15. A variety of methods are available for monitoring impurities. The primary criterion is the ability to differentiate between the compounds of interest. This requirement reduces the availability of methods primarily to spectroscopic and separation methods or a combination thereof. 15
  • 16. Spectroscopic methods The following spectroscopic methods can be used: ▪ Ultraviolet (UV) ▪ Infrared (IR) ▪ Nuclear magnetic resonance (NMR) ▪ Mass spectrometry (MS) 16
  • 17. SEPARATION METHODS The following separation methods can be used: ▪ Thin-layer chromatography (TLC) ▪ Gas chromatography (GC) ▪ High-pressure liquid chromatography (HPLC) ▪ Capillary electrophoresis (CE) ▪ Supercritical fluid chromatography (SFC) 17
  • 18. TLC: A broad range of compounds can be resolved using TLC by utilizing a variety of different plates and mobile phases. The primary difficulties related to this method are limited resolution, detection, and ease of quantification. The greatest advantages are the ease of use and low cost. GC: Gas chromatography is a very useful technique for quantification. It can provide the desired resolution, selectivity, and ease of quantification. However, the primary limitation is that the sample must be volatile or has to be made volatile by derivatization. This technique is very useful for organic volatile impurities. HPLC: This is a useful technique with applications that have been significantly extended for the pharmaceutical chemist by the use of a variety of detectors such as fluorescence, electrometric, MS, etc 18
  • 19. Capillary electrophoresis : a useful technique when very low quantities of samples are available and high resolution is required. The primary difficulty is assuring reproducibility of the injected samples. Supercritical fluid chromatography: offers some of the advantages of GC in terms of detection and HPLC in terms of separations, in that volatility of the sample is not of paramount importance. This technique is still evolving, and its greatest application has been found in the extraction of samples. 19
  • 20. Hyphenated methods ▪ GC–MS ▪ LC–MS ▪ LC–DAD–MS ▪ LC–NMR ▪ LC–DAD–NMR–MS ▪ LC–MS–MS 20
  • 21. Impurity profiling The name impurity profiling is commonly reflected to be a set of analytical activities targeting at the detection, identification or structure characterisation and quantitative estimation of organic, inorganic impurities, and residual solvents, in drug substances as well as in a drug products. Reporting, identification and qualification of impurities are required for determining the biological safety of each impurity. 21
  • 22. Samples to be profiled : Impurity profiling should be done for the following samples: ▪ Active ingredient ▪ Process check (synthesis or formulation) ▪ Final product. 22
  • 23. Components seen in a profile : Ideally, an impurity profile should show the following: ▪ Synthesis-related impurities ▪ Formulation-related impurities ▪ Degradation products ▪ Interaction products 23
  • 24. Isolating impurities The following methods have been used for isolation of impurities: ▪ Solid-phase extraction ▪ Liquid–liquid extraction ▪ Accelerated solvent extraction ▪ Supercritical fluid extraction ▪ Column chromatography ▪ Flash chromatography ▪ Thin-layer chromatography ▪ Gas chromatography ▪ High-pressure liquid chromatography ▪ Capillary electrophoresis ▪ Supercritical fluid chromatography. 24
  • 25. Isolation should be initiated based on simple extraction or partition methods. It may be possible to extract impurities selectively on the basis of acidity, basicity, or neutrality. The extraction process usually involves liquid–liquid extraction, where one phase is an aqueous solution and the other is an organic phase that is nonpolar. By appropriate adjustment of the pH of the aqueous solution, one can extract acidic, basic, or neutral impurities. Further separations can be made by chromatographic methods. Frequently, the isolation methods tend to be the same methods that are used for analysis. 25
  • 26. Characterization of impurities The characterization of impurities is generally achieved by the following means: ▪ Matching retention data ▪ UV ▪ IR ▪ NMR ▪ MS Once an impurity has been detected, it becomes necessary to estimate its content. Detectability frequently means that a given component provides a signal at least twice that of background noise or the baseline. 26
  • 27. 27
  • 28. Application of Impurity Profiling Numerous applications have been sought in the areas of drug designing and in monitoring quality, stability, and safety of pharmaceutical compounds, whether produced synthetically, extracted from natural products or produced by recombinant methods. The applications include alkaloids, amines, amino acids, analgesics, antibacterials, anticonvulsants, antidepressant, tranquilizers, antineoplastic agents, local anesthetics, macromolecules, steroids etc. Some commonly found impurities in drug and their identification method are: 28
  • 29. 29
  • 30. 30